<li>5-htp<p>venlafaxine and 5-htp both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>abiraterone<p>abiraterone increases levels of venlafaxine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.</p></li><li>aceclofenac<p>venlafaxine, aceclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>acemetacin<p>venlafaxine, acemetacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>almotriptan<p>almotriptan and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>amisulpride<p>amisulpride and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amitriptyline<p>amitriptyline and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amoxapine<p>amoxapine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amphetamine<p>amphetamine increases toxicity of venlafaxine by serotonin levels. Use Caution/Monitor. Closely monitor for signs and symptoms of serotonin syndrome (eg, agitation, tremor, tachycardia).</p></li><li>aripiprazole<p>venlafaxine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>aspirin<p>venlafaxine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin rectal<p>venlafaxine, aspirin rectal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>venlafaxine, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>atomoxetine<p>venlafaxine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>buprenorphine subdermal implant<p>venlafaxine, buprenorphine subdermal implant.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.</p></li><li>bupropion<p>bupropion will increase the level or effect of venlafaxine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>carvedilol<p>venlafaxine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>celecoxib<p>venlafaxine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>chlorpromazine<p>venlafaxine will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>chlorpromazine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>choline magnesium trisalicylate<p>venlafaxine, choline magnesium trisalicylate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>clarithromycin<p>clarithromycin and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>clobazam<p>clobazam will increase the level or effect of venlafaxine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. </p></li><li>clomipramine<p>venlafaxine will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>clomipramine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>clopidogrel<p>venlafaxine increases effects of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SNRIs affect platelet activation; coadministration of SNRIs with clopidogrel may increase the risk of bleeding.</p></li><li>cocaine<p>venlafaxine and cocaine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>codeine<p>venlafaxine will increase the level or effect of codeine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>crofelemer<p>crofelemer increases levels of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyproheptadine<p>venlafaxine increases and cyproheptadine decreases serotonin levels. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of venlafaxine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>dasatinib<p>dasatinib and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>desipramine<p>venlafaxine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>desipramine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dexfenfluramine<p>venlafaxine and dexfenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dextroamphetamine<p>venlafaxine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely.<span><br><br></span>venlafaxine and dextroamphetamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dichlorphenamide<p>dichlorphenamide and venlafaxine both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>venlafaxine, diclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>diflunisal<p>venlafaxine, diflunisal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>dihydroergotamine<p>venlafaxine and dihydroergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dihydroergotamine intranasal<p>venlafaxine and dihydroergotamine intranasal both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dofetilide<p>dofetilide and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dolasetron<p>dolasetron and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>dosulepin<p>dosulepin and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>doxepin<p>doxepin and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dronedarone<p>dronedarone and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>droperidol<p>droperidol and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>duloxetine<p>venlafaxine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>eletriptan<p>eletriptan and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>eliglustat<p>eliglustat increases levels of venlafaxine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of venlafaxine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>epinephrine<p>epinephrine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>epinephrine racemic<p>epinephrine racemic and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ergotamine<p>venlafaxine and ergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>erythromycin base<p>erythromycin base and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin stearate<p>erythromycin stearate and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>etodolac<p>venlafaxine, etodolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>etoricoxib<p>venlafaxine, etoricoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fenbufen<p>venlafaxine, fenbufen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fenfluramine<p>venlafaxine and fenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>fenoprofen<p>venlafaxine, fenoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>flecainide<p>venlafaxine will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>flecainide and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>fluconazole<p>fluconazole and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>fluoxetine<p>fluoxetine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>fluphenazine<p>venlafaxine will increase the level or effect of fluphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>flurbiprofen<p>venlafaxine, flurbiprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fluvoxamine<p>fluvoxamine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>formoterol<p>formoterol and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>foscarnet<p>foscarnet and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>frovatriptan<p>frovatriptan and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>green tea<p>green tea, venlafaxine. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding.</p></li><li>haloperidol<p>venlafaxine will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>haloperidol and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>hydrocodone<p>venlafaxine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>hydromorphone<p>venlafaxine will increase the level or effect of hydromorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ibuprofen<p>venlafaxine, ibuprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>iloperidone<p>venlafaxine will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>iloperidone and venlafaxine both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>iloperidone increases levels of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>imipramine<p>venlafaxine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>imipramine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>indomethacin<p>venlafaxine, indomethacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>isoniazid<p>venlafaxine and isoniazid both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>itraconazole<p>itraconazole and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ketoconazole<p>ketoconazole and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ketoprofen<p>venlafaxine, ketoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac<p>venlafaxine, ketorolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac intranasal<p>venlafaxine, ketorolac intranasal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>l-tryptophan<p>venlafaxine and l-tryptophan both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lapatinib<p>lapatinib and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>levofloxacin<p>levofloxacin and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>lithium<p>venlafaxine and lithium both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lofepramine<p>venlafaxine will increase the level or effect of lofepramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>lofepramine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>lopinavir<p>lopinavir increases levels of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity.</p></li><li>loratadine<p>venlafaxine will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lorcaserin<p>lorcaserin will increase the level or effect of venlafaxine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lornoxicam<p>venlafaxine, lornoxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>lsd<p>venlafaxine and lsd both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lumefantrine<p>lumefantrine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>lurasidone<p>lurasidone, venlafaxine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.</p></li><li>maprotiline<p>maprotiline and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>meclofenamate<p>venlafaxine, meclofenamate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mefenamic acid<p>venlafaxine, mefenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>meloxicam<p>venlafaxine, meloxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>methadone<p>methadone and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>methamphetamine<p>venlafaxine will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>metoprolol<p>venlafaxine will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mexiletine<p>venlafaxine will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mianserin<p>mianserin and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>mibefradil<p>venlafaxine will increase the level or effect of mibefradil by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of venlafaxine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirtazapine<p>venlafaxine and mirtazapine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>morphine<p>venlafaxine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>venlafaxine and morphine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>moxifloxacin<p>moxifloxacin and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nabumetone<p>venlafaxine, nabumetone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naproxen<p>venlafaxine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naratriptan<p>naratriptan and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>nebivolol<p>venlafaxine will increase the level or effect of nebivolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>nilotinib<p>nilotinib and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nortriptyline<p>nortriptyline and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>octreotide<p>octreotide and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>octreotide (antidote)<p>octreotide (antidote) and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ofloxacin<p>ofloxacin and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>oxaprozin<p>venlafaxine, oxaprozin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>oxycodone<p>venlafaxine will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>oxymorphone<p>venlafaxine will increase the level or effect of oxymorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>paliperidone<p>paliperidone and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>panobinostat<p>panobinostat will increase the level or effect of venlafaxine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Panobinostat can increase the levels and effects of sensitive CYP2D6 substrates or those with a narrow therapeutic index CYP2D6.</p></li><li>parecoxib<p>venlafaxine, parecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>paroxetine<p>paroxetine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b, venlafaxine. Other (see comment). Use Caution/Monitor. 
Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.</p></li><li>pentazocine<p>venlafaxine and pentazocine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>perphenazine<p>venlafaxine will increase the level or effect of perphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>piroxicam<p>venlafaxine, piroxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>posaconazole<p>posaconazole and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>prochlorperazine<p>venlafaxine will increase the level or effect of prochlorperazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>prochlorperazine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>promazine<p>promazine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>promethazine<p>promethazine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>propafenone<p>venlafaxine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>propranolol<p>venlafaxine will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>protriptyline<p>protriptyline and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ranolazine<p>ranolazine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>risperidone<p>venlafaxine will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>risperidone and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir increases levels of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>rizatriptan<p>rizatriptan and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>romidepsin<p>romidepsin and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>salicylates (non-asa)<p>venlafaxine, salicylates (non-asa).
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>salsalate<p>venlafaxine, salsalate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>same<p>venlafaxine and same both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sertindole<p>venlafaxine will increase the level or effect of sertindole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>sertindole and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>venlafaxine, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>venlafaxine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sulfamethoxazole<p>sulfamethoxazole and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>sulfasalazine<p>venlafaxine, sulfasalazine.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sulindac<p>venlafaxine, sulindac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sumatriptan<p>sumatriptan and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan intranasal<p>sumatriptan intranasal and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan transdermal<p>sumatriptan transdermal and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>tamoxifen<p>venlafaxine decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.</p></li><li>tapentadol<p>venlafaxine and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>telavancin<p>telavancin and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>telithromycin<p>telithromycin and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>timolol<p>venlafaxine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>tipranavir<p>tipranavir, venlafaxine.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tolfenamic acid<p>venlafaxine, tolfenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tolmetin<p>venlafaxine, tolmetin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tramadol<p>venlafaxine and tramadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>trazodone<p>trazodone and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trifluoperazine<p>venlafaxine will increase the level or effect of trifluoperazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>trifluoperazine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trimethoprim<p>trimethoprim and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>trimipramine<p>trimipramine and venlafaxine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>tropisetron<p>tropisetron and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>valerian<p>valerian and venlafaxine both increase  sedation. Use Caution/Monitor.</p></li><li>vorapaxar<p>venlafaxine, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion .</p></li><li>voriconazole<p>venlafaxine and voriconazole both increase  QTc interval. Use Caution/Monitor.</p></li><li>ziprasidone<p>venlafaxine and ziprasidone both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>zolmitriptan<p>zolmitriptan and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li>